Valuation: Tarsus Pharmaceuticals, Inc.

Market Cap 3.74B 3.42B 3.16B 2.85B 5.37B 350B 5.58B 38.14B 15.08B 189B 14.05B 13.75B 596B P/E 2026 *
-4.88x
P/E 2027 * 211x
Enterprise Value 3.41B 3.11B 2.88B 2.6B 4.89B 319B 5.09B 34.78B 13.75B 172B 12.81B 12.54B 544B EV / Sales 2026 *
4.61x
EV / Sales 2027 * 3.73x
Free-Float
96.36%
Yield 2026 *
-
Yield 2027 * -
1 day-2.88%
1 week-1.06%
Current month+1.47%
1 month+11.58%
3 months+6.93%
6 months+20.90%
Current year-7.24%
1 week 75.2
Extreme 75.2
81.35
1 month 65.34
Extreme 65.3425
81.35
Current year 53.89
Extreme 53.89
91.53
1 year 53.89
Extreme 53.89
91.53
3 years 15.6
Extreme 15.6
91.53
5 years 10.8
Extreme 10.8001
91.53
10 years 10.8
Extreme 10.8001
91.53
Manager TitleAgeSince
Chief Executive Officer 48 2018-08-31
Director of Finance/CFO 65 2023-04-23
Chief Tech/Sci/R&D Officer 47 2024-11-03
Director TitleAgeSince
Chairman 48 2022-12-01
Director/Board Member 71 2019-11-30
Director/Board Member 80 2016-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
11/3/26 Free

Executive/Senior Manager

17,265 0.0350%
11/1/26 Other

Executive/Senior Manager

103,767 0.2105%
9/15/26 Exercice

Director

604 0.0014%
Change 5-day change 1-year change 3-year change Capi.($)
-2.88%-1.06%-1.33%+302.70% 3.86B
-2.32%-3.79%+34.24%+133.69% 1,261B
-2.15%-2.75%+36.35%+82.05% 671B
-2.33%-3.04%+22.29%+106.80% 518B
-0.69%+0.37%+31.53%+69.78% 387B
-3.90%-6.39%+42.88%+35.41% 353B
-1.35%-0.95%+28.90%+56.34% 300B
-1.13%-1.80%+0.59%+33.00% 283B
-3.07%-5.17%+29.04%+67.26% 248B
-0.75%-0.44%+32.87%+123.96% 211B
Average -2.06%-1.75%+25.74%+101.10% 424B
Weighted average by Cap. -2.10%-2.34%+30.56%+91.76%

Financials

2026 *2027 *
Net sales 741M 676M 625M 564M 1.06B 69.29B 1.1B 7.55B 2.99B 37.4B 2.78B 2.72B 118B 942M 859M 794M 717M 1.35B 88.04B 1.4B 9.59B 3.79B 47.52B 3.53B 3.46B 150B
Net income -708M -646M -597M -539M -1.01B -66.17B -1.05B -7.21B -2.85B -35.71B -2.66B -2.6B -113B 18.37M 16.75M 15.49M 13.98M 26.33M 1.72B 27.37M 187M 73.95M 927M 68.92M 67.47M 2.93B
Net Debt -330M -301M -278M -251M -473M -30.85B -492M -3.36B -1.33B -16.65B -1.24B -1.21B -52.58B -232M -212M -196M -177M -333M -21.7B -346M -2.36B -935M -11.71B -871M -853M -36.98B
Projected Income Statement - Annual - Tarsus Pharmaceuticals, Inc.
Logo Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company's lead product candidate, XDEMVY, is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. It is investigating the development of its product candidates to address targeted diseases with medical needs, which include TP-04, a novel ophthalmic gel formulation of lotilaner for the potential treatment of Ocular Rosacea, and TP-05, a novel investigational oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction. It is also developing IRX-101, an investigational ocular antiseptic.
Employees
370
Date Price Change Volume
26-11-18 $75.95 -2.88% 456,219
26-11-17 $78.20 -0.61% 542,221
26-11-16 $78.68 -1.99% 874,965
26-11-13 $80.28 +4.41% 732,093
26-11-12 $76.89 +0.17% 445,181
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Tarsus Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
75.95USD
Average target price
103.44USD
Spread / Average Target
+36.20%
  1. Stock Market
  2. Stocks
  3. TARS Stock